Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy.
Cancer immunotherapy
antitumor immune response.
immune microenvironment programming
nanoparticles
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
06
2019
accepted:
12
08
2019
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
15
9
2020
Statut:
epublish
Résumé
Immunotherapy is rapidly maturing towards extensive clinical use. However, it does not work well in large patient populations because of an immunosuppressed microenvironment and limited reinvigoration of antitumor immunity. The tumor microenvironment is a complex milieu in which the principles of physiology and anatomy are defied and which is considered an immune-privileged site promoting T cell exhaustion. Tremendous research interest exists in developing nanoparticle-based approaches to modulate antitumor immune responses. The increasing use of immunotherapies in the clinic requires robust programming of immune cells to boost antitumor immunity. This review summarizes recent advances in the engineering of nanoparticles for improved anticancer immunotherapy. It discusses emerging nanoparticle-based approaches for the modulation of tumor cells and immune cells, such as dendritic cells, T cells and tumor-associated macrophages, with the intention to overcome challenges currently faced in the clinic. Furthermore, this review describes potentially curative combination therapeutic approaches to provoke effective tumor antigen-specific immune responses. We foresee a future in which improvement in patient's surveillance will become a mainstream practice.
Identifiants
pubmed: 31754376
doi: 10.7150/thno.37568
pii: thnov09p7981
pmc: PMC6857062
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7981-8000Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Nat Med. 2003 Mar;9(3):269-77
pubmed: 12612576
ACS Nano. 2018 Nov 27;12(11):11041-11061
pubmed: 30481959
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Cell Rep. 2015 Oct 13;13(2):412-24
pubmed: 26411680
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Cancer Lett. 2016 Aug 28;379(1):32-8
pubmed: 27235608
Adv Mater. 2018 Mar;30(10):
pubmed: 29333661
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
Nat Nanotechnol. 2019 Jan;14(1):89-97
pubmed: 30531990
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Adv Mater. 2013 Jul 12;25(26):3508-25
pubmed: 23703805
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Nat Immunol. 2016 Mar;17(3):215-6
pubmed: 26882248
Cell. 2009 Jul 10;138(1):30-50
pubmed: 19596234
Chem Soc Rev. 2019 Jan 2;48(1):351-381
pubmed: 30465669
Nat Biotechnol. 2015 Jan;33(1):44-5
pubmed: 25574635
Nat Commun. 2017 Nov 14;8(1):1482
pubmed: 29133898
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19902-7
pubmed: 24248387
Cell. 2010 Mar 19;140(6):798-804
pubmed: 20303871
Nat Biomed Eng. 2018 Nov;2(11):793-794
pubmed: 31015619
J Immunol. 2003 Feb 1;170(3):1257-66
pubmed: 12538684
Oncogene. 2008 Oct 6;27(45):5932-43
pubmed: 18836474
Nat Nanotechnol. 2017 Aug;12(8):813-820
pubmed: 28416815
Eur J Immunol. 2003 Nov;33(11):3117-26
pubmed: 14579280
Nat Rev Cancer. 2003 Sep;3(9):666-75
pubmed: 12951585
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Nat Mater. 2018 Sep;17(9):761-772
pubmed: 30104668
Oncoimmunology. 2015 Apr 1;4(7):e1016700
pubmed: 26140242
Nat Rev Drug Discov. 2015 Sep;14(9):603-22
pubmed: 26228631
ACS Nano. 2015 Jan 27;9(1):16-30
pubmed: 25469470
Nano Lett. 2016 Sep 14;16(9):5503-13
pubmed: 27525587
Blood. 2007 Jun 1;109(11):4839-45
pubmed: 17299090
Nat Commun. 2019 Apr 23;10(1):1899
pubmed: 31015397
Nat Med. 1999 Nov;5(11):1249-55
pubmed: 10545990
Nat Rev Cancer. 2017 May;17(5):286-301
pubmed: 28338065
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Clin Cancer Res. 2010 Jun 15;16(12):3100-4
pubmed: 20421432
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
J Control Release. 2014 Oct 10;191:24-33
pubmed: 24698946
J Control Release. 2014 Oct 28;192:209-18
pubmed: 25068703
EMBO J. 2012 Mar 7;31(5):1062-79
pubmed: 22252128
Nature. 2014 Mar 27;507(7493):508-12
pubmed: 24553136
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Adv Mater. 2018 Sep;30(38):e1803001
pubmed: 30063262
Nat Commun. 2018 Oct 5;9(1):4092
pubmed: 30291237
Immunol Rev. 2007 Dec;220:47-59
pubmed: 17979839
Clin Cancer Res. 2010 Dec 15;16(24):6139-49
pubmed: 20876255
Adv Funct Mater. 2014 Jul 16;24(27):4206-4220
pubmed: 25477774
Sci Transl Med. 2015 Jun 10;7(291):291ra94
pubmed: 26062846
Sci Adv. 2018 Apr 18;4(4):eaao1736
pubmed: 29675465
Cancer Res. 1991 Sep 1;51(17):4712-5
pubmed: 1873815
Nat Commun. 2017 Nov 23;8(1):1747
pubmed: 29170511
Curr Opin Immunol. 2009 Apr;21(2):179-86
pubmed: 19264470
Cancer Res. 2014 Dec 1;74(23):6771-83
pubmed: 25297630
Nat Rev Cancer. 2016 Jan;16(1):56-66
pubmed: 26694936
Nano Lett. 2017 Dec 13;17(12):7684-7690
pubmed: 29160717
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Nat Rev Mater. 2019 Jun;4(6):415-428
pubmed: 32523780
Nano Lett. 2018 May 9;18(5):3250-3258
pubmed: 29683683
Am J Pathol. 2005 Sep;167(3):627-35
pubmed: 16127144
Nat Rev Mater. 2017;2:
pubmed: 29075517
Nat Biomed Eng. 2018 Aug;2(8):611-621
pubmed: 31015634
J Am Chem Soc. 2018 May 2;140(17):5670-5673
pubmed: 29665677
Nat Rev Cancer. 2016 Aug 23;16(9):566-81
pubmed: 27550819
Nature. 2014 Mar 27;507(7493):519-22
pubmed: 24531764
Nat Biotechnol. 2018 Sep;36(8):707-716
pubmed: 29985479
Nat Biotechnol. 2007 Oct;25(10):1159-64
pubmed: 17873867
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Adv Mater. 2019 Apr;31(17):e1806957
pubmed: 30856290
Front Immunol. 2013 Oct 10;4:321
pubmed: 24133494
Annu Rev Immunol. 2006;24:175-208
pubmed: 16551247
Adv Mater. 2019 Apr;31(14):e1805888
pubmed: 30762908
Blood. 2010 Apr 29;115(17):3520-30
pubmed: 20197554
Nat Rev Genet. 2014 Aug;15(8):541-55
pubmed: 25022906
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Nat Mater. 2018 Jun;17(6):528-534
pubmed: 29507416
Nat Commun. 2016 Nov 07;7:13443
pubmed: 27819653
Nat Rev Immunol. 2015 Feb;15(2):73-86
pubmed: 25614318
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Cancer Res. 2008 Feb 1;68(3):889-92
pubmed: 18245491
Nat Rev Clin Oncol. 2017 Mar;14(3):155-167
pubmed: 27644321
Adv Mater. 2018 May;30(22):e1707112
pubmed: 29656492
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Nano Lett. 2016 Apr 13;16(4):2334-40
pubmed: 26999507
Cancer Res. 2006 Jun 1;66(11):5527-36
pubmed: 16740684
Nat Med. 2015 Oct;21(10):1209-15
pubmed: 26322579
Annu Rev Med. 2014;65:333-47
pubmed: 24274181
Nat Commun. 2017 Dec 5;8(1):1954
pubmed: 29203865
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Nat Biomed Eng. 2018 Nov;2(11):831-840
pubmed: 31015615
Nat Nanotechnol. 2017 Jul;12(7):648-654
pubmed: 28436963
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Nat Nanotechnol. 2019 Mar;14(3):269-278
pubmed: 30664751
J Control Release. 2013 Dec 10;172(2):426-35
pubmed: 23770010
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
J Transl Med. 2013 Oct 05;11:246
pubmed: 24093426
Biomaterials. 2019 Jan;190-191:111-120
pubmed: 30415018
Adv Funct Mater. 2015 Jul 15;25(27):4183-4194
pubmed: 27340392
Cancer Res. 2012 Aug 15;72(16):3919-27
pubmed: 22751466
Curr Opin Immunol. 2016 Apr;39:1-6
pubmed: 26609943
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
Nature. 2009 Nov 26;462(7272):449-60
pubmed: 19940915
Nat Med. 2015 Oct;21(10):1122-3
pubmed: 26444633
Nat Commun. 2017 Oct 12;8(1):902
pubmed: 29026068
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Mater. 2017 Apr;16(4):489-496
pubmed: 28024156
Nat Nanotechnol. 2011 Sep 11;6(10):675-82
pubmed: 21909083
Nat Biomed Eng. 2018 Aug;2(8):600-610
pubmed: 31015630
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Nat Commun. 2017 Nov 27;8(1):1811
pubmed: 29180759
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Breast Cancer Res. 2009;11(6):R84
pubmed: 19919679
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
Nat Rev Immunol. 2018 Sep;18(9):545-558
pubmed: 29921905
Chem Rev. 2015 Oct 14;115(19):11109-46
pubmed: 26154342
Nat Commun. 2016 Oct 21;7:13193
pubmed: 27767031
J Clin Invest. 2014 Jun;124(6):2425-40
pubmed: 24812664
Acc Chem Res. 2019 Jun 18;52(6):1543-1554
pubmed: 31120725
Nat Biotechnol. 2015 Jan;33(1):64-72
pubmed: 25485616
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nano Lett. 2017 Dec 13;17(12):7387-7393
pubmed: 29144754
Front Biosci (Elite Ed). 2012 Jan 01;4:734-45
pubmed: 22201909
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
Springer Semin Immunopathol. 2005 Jan;26(3):231-46
pubmed: 15609001
J Biomed Res. 2018 Sep 29;32(5):317-326
pubmed: 28866656
Nat Commun. 2019 May 2;10(1):2025
pubmed: 31048681
Curr Opin Immunol. 2012 Apr;24(2):207-12
pubmed: 22236695
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
ACS Nano. 2016 Aug 23;10(8):7339-50
pubmed: 27390910
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Nat Med. 2001 Jan;7(1):94-100
pubmed: 11135622
Vaccines (Basel). 2015 Aug 27;3(3):662-85
pubmed: 26350600
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344
Adv Mater. 2019 Jun;31(23):e1900192
pubmed: 30916367
J Gene Med. 2019 Jul;21(7):e3092
pubmed: 30991453